Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

MONTREAL, Jan. 8 /PRNewswire/ - Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2 study of AEG35156, their targeted antisense therapeutic in mid-stage development for multiple oncology indications.

The study, entitled "A Phase 2, Multicenter, Open-Label, Randomized Study of the X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 Given In Combination With Carboplatin/Paclitaxel or the Combination of Carboplatin/Paclitaxel Alone In Patients With Advanced Non Small Cell Lung Cancer" is being conducted in the United States in collaboration with U.S. Oncology and additional sites will be opened in Canada. The Principal Investigator of this study is Dr. Robert M. Jotte, of the Rocky Mountain Cancer Center in Denver, Colorado.

The primary objective of this study is to compare the efficacy of the standard of care for this patient population to the standard of care in combination with AEG35156. Recruitment for this trial is expected to be completed prior to the end of 2009.

"Preliminary evidence of activity was observed in the Phase 1 portion of this study and encouraged us to amend the clinical protocol to provide for a control arm for the Phase 2 portion of the study" stated Dr. Jacques Jolivet, Senior Vice-President of Clinical Development of Aegera.

"Our clinical program around AEG35156 continues to accelerate and expand as we seek to move this therapeutic forward to more advanced stages of clinical development," added Aegera's President and Chief Executive Officer, Dr. Michael J. Berendt. "The initiation of this randomized Phase 2 study in lung cancer follows very shortly after our publication of positive clinical data from our Phase 1/2 study in AML at the recent ASH conference in San Francisco and represents the first of multiple new clinical trials for this innovative therapy that we hope to announce over the course of 2009."

About AEG35156

Ca
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that it will ... May 7, 2015 after the close of the U.S. ... and webcast on Thursday, May 7, 2015 at 4:30 ... results and recent corporate developments. For both ...
(Date:4/30/2015)... 30, 2015 Available in select ... http://www.lespausa.com , Phytomer’s DOUCEUR INTEMPORELLE Restorative Shield ... skin while battling the weakening threat of inflammaging, ... is formulated with star ingredient GLYCOSEA, a complex ... a complex of soothing minerals and trace elements. ...
(Date:4/29/2015)... April 30, 2015 According to ... Market by Product (Portable & Non-Portable), Component (Accelerometer, ... Automotive, Chemical, Metal & Mining, & Others), & ... market is expected to reach $1,453.76 Million by ... 71 market data tables and 92 figures spread ...
(Date:4/29/2015)... , April 29, 2015 Cambrex Corporation (NYSE: ... will be released on Friday, May 1, 2015 before the ... The Company will host a conference call to discuss ... When: , Friday, May 1, 2015 ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 ...
Breaking Biology Technology:Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4
... integrating patient medical information securely and seamlessly across multiple ... the Midwest. , ,A recent partnership between Symphony ... CareEvolution seeks to implement a novel clinical information-sharing ... so-called "federated" model utilizes a peer-to-peer record locator service ...
... A Wisconsin-based portal to educational information about books ... from the Association of Educational Publishers . ... supplemental educational resources for nearly three decades, honored ... category titled "Portal for Young Adults and Children." ...
... generation ago, then-Gov. Lee Dreyfus made a few waves ... should become "the blue-eyed Arabs of the Upper Midwest" ... , ,Like many of his ideas, often delivered ... about them, this Dreyfus proposal simultaneously stirred the imagination ...
Cached Biology Technology:Symphony Corp. and CareEvolution to partner 2Fresh water could be a deep economic wellspring for Wisconsin 2Fresh water could be a deep economic wellspring for Wisconsin 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 2015 SoundView Technology Group issues a new research ... ) Wocket smart wallet. SoundView was one of the selected user ... with the Wocket in multiple scenarios and outlets. ... other retailers, making both debit and credit card payments.  ... "If the company meets their plans in 2015, it would ...
(Date:3/23/2015)... -- In the 2014 fiscal year, irs.gov recorded over $100 ... accounts for a fraction of the estimated losses for ... $11 billion globally. The polygraph has traditionally been used ... Investor Mark Saint Juste along with former ... partnered to administer the test in a new way: ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Richer, speaking at his 4th annual Nutrition & The Eye ... the University of Missouri in St. Louis, says molecular medicine ... when all other therapies have been exhausted. "These nutritional ... in cardiology , cancer research and some human studies", Dr ...
... 14, 2011 Novocure today announced that the ... NovoTTF-100A System (NovoTTF) for the treatment of adult ... tumor recurrence after receiving chemotherapy. The portable, ... patients maintain their normal daily activities. The NovoTTF ...
... A team led by researchers at the National Institutes of ... the melanoma genome, the DNA code of the deadliest form ... using whole-exome sequencing, an approach that decodes the 1-2 percent ... in the April 15, 2011, early online issue of ...
Cached Biology News:Low-cost molecular medicine should be included in modern eye physicians' tool kit 2FDA approves the NovoTTF-100A system for the treatment of patients with recurrent glioblastoma multiforme (GBM) brain tumors 2NIH researchers complete whole-exome sequencing of skin cancer 2NIH researchers complete whole-exome sequencing of skin cancer 3NIH researchers complete whole-exome sequencing of skin cancer 4NIH researchers complete whole-exome sequencing of skin cancer 5
TP-1 (NDOG1)...
Ras-related C3 botulinum toxin substrate 1...
Mouse monoclonal [6G11] to Cytohesin 1 + 2 ( Abpromise for all tested applications)....
... Express Cloning Checker Kits provide two ... after transformation without time-consuming plasmid preparation. By ... I, all you need to do is ... bacteria directly from the transformation plates into ...
Biology Products: